Altimmune Free Cash Flow per Share vs Accounts Payable Analysis
| ALT Stock | USD 6.89 0.15 2.13% |
Altimmune financial indicator trend analysis is way more than just evaluating Altimmune prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Altimmune is a good investment. Please check the relationship between Altimmune Free Cash Flow Per Share and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.
Free Cash Flow Per Share vs Accounts Payable
Free Cash Flow per Share vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Altimmune Free Cash Flow per Share account and Accounts Payable. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Altimmune's Free Cash Flow per Share and Accounts Payable is -0.04. Overlapping area represents the amount of variation of Free Cash Flow per Share that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Altimmune, assuming nothing else is changed. The correlation between historical values of Altimmune's Free Cash Flow per Share and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow per Share of Altimmune are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Free Cash Flow per Share i.e., Altimmune's Free Cash Flow per Share and Accounts Payable go up and down completely randomly.
Correlation Coefficient | -0.04 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Free Cash Flow Per Share
The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.Accounts Payable
An accounting item on the balance sheet that represents Altimmune obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Altimmune are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most indicators from Altimmune's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Altimmune current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.At this time, Altimmune's Tax Provision is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 44.70 in 2024, despite the fact that Enterprise Value Over EBITDA is likely to grow to (5.31).
| 2021 | 2022 | 2023 | 2024 (projected) | Research Development | 74.5M | 70.5M | 65.3M | 68.6M | Depreciation And Amortization | 11.2M | 2.8M | 477K | 453.2K |
Altimmune fundamental ratios Correlations
Click cells to compare fundamentals
Altimmune Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Altimmune fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 54.1M | 245.1M | 218.9M | 206.9M | 210.6M | 221.2M | |
| Other Current Liab | 3.6M | 11.0M | 6.1M | 11.8M | 9.6M | 17.1M | |
| Total Current Liabilities | 3.9M | 12.0M | 18.3M | 17.1M | 12.1M | 21.2M | |
| Total Stockholder Equity | 45.5M | 225.9M | 199.1M | 185.3M | 194.1M | 203.8M | |
| Net Debt | (7.2M) | (114.1M) | (188.8M) | (110.0M) | (134.5M) | (127.8M) | |
| Retained Earnings | (137.4M) | (186.4M) | (293.2M) | (377.9M) | (466.3M) | (443.0M) | |
| Accounts Payable | 18.2K | 612.3K | 2.0M | 4.8M | 2.1M | 1.5M | |
| Cash | 9.0M | 115.9M | 190.3M | 111.1M | 135.2M | 141.9M | |
| Cash And Short Term Investments | 37.2M | 215.9M | 190.3M | 184.9M | 197.9M | 207.7M | |
| Common Stock Total Equity | 876.0 | 1.5K | 3.7K | 4.1K | 4.7K | 3.9K | |
| Common Stock Shares Outstanding | 13.1M | 25.6M | 41.3M | 46.9M | 53.2M | 55.9M | |
| Liabilities And Stockholders Equity | 54.1M | 245.1M | 218.9M | 206.9M | 210.6M | 221.2M | |
| Other Current Assets | 504.4M | 2.0B | 13.4B | 5.4M | 6.8M | 6.5M | |
| Other Stockholder Equity | 187.9M | 417.3M | 497.3M | 568.4M | 665.4M | 698.7M | |
| Total Liab | 8.5M | 19.2M | 19.7M | 21.6M | 16.5M | 27.3M | |
| Total Current Assets | 39.4M | 230.3M | 204.1M | 192.8M | 209.5M | 220.0M | |
| Common Stock | 1.5K | 3.7K | 4.1K | 5K | 7K | 4.2K | |
| Other Assets | 128.5K | 977.2K | 73.8K | 19K | 1.0 | 0.95 | |
| Non Current Liabilities Total | 4.6M | 7.2M | 1.5M | 4.6M | 4.4M | 4.7M | |
| Short Term Debt | 259.4K | 356.7K | 411.5K | 452K | 496K | 471.2K | |
| Short Long Term Debt Total | 1.7M | 1.8M | 1.5M | 1.1M | 671K | 637.5K | |
| Property Plant And Equipment Net | 1.8M | 2.0M | 1.4M | 1.1M | 1.0M | 1.5M | |
| Non Current Assets Total | 14.7M | 14.9M | 14.7M | 14.1M | 1.1M | 1.1M | |
| Non Currrent Assets Other | 128.5K | 73.4K | 872.0K | 615K | 100.0K | 95.0K | |
| Net Receivables | 1.7M | 12.4M | 5.8M | 2.5M | 4.9M | 5.0M | |
| Property Plant And Equipment Gross | 1.8M | 2.0M | 1.4M | 2.6M | 2.6M | 1.6M | |
| Accumulated Other Comprehensive Income | (5.0M) | (5.0M) | (5.0M) | (5.2M) | (5.0M) | (4.8M) | |
| Intangible Assets | 12.7M | 12.8M | 12.4M | 12.4M | 14.3M | 11.8M | |
| Net Tangible Assets | 32.8M | 213.1M | 186.7M | 172.9M | 198.8M | 208.7M | |
| Long Term Debt | 1.9M | 1.9M | 1.8M | 1.5M | 1.7M | 1.5M | |
| Retained Earnings Total Equity | (116.9M) | (137.4M) | (186.4M) | (293.2M) | (337.1M) | (354.0M) | |
| Capital Surpluse | 170.2M | 187.9M | 417.3M | 497.3M | 571.9M | 600.5M | |
| Property Plant Equipment | 1.1M | 1.1M | 1.4M | 1.7M | 1.9M | 2.0M | |
| Long Term Debt Total | 1.9M | 1.9M | 1.8M | 1.5M | 1.7M | 2.0M | |
| Non Current Liabilities Other | 2.8M | 5.4M | 1.5M | 3.9M | 4.2M | 4.4M | |
| Other Liab | 3.1M | 7.2M | 330.5K | 3.9M | 4.5M | 3.3M |
Pair Trading with Altimmune
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Altimmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altimmune will appreciate offsetting losses from the drop in the long position's value.Moving together with Altimmune Stock
| 0.74 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
| 0.7 | KZR | Kezar Life Sciences Financial Report 9th of May 2024 | PairCorr |
Moving against Altimmune Stock
| 0.48 | MRKR | Marker Therapeutics | PairCorr |
The ability to find closely correlated positions to Altimmune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Altimmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Altimmune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Altimmune to buy it.
The correlation of Altimmune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Altimmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Altimmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Altimmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Altimmune Stock analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
Is Altimmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.66) | Revenue Per Share 0.008 | Quarterly Revenue Growth 180 | Return On Assets (0.25) | Return On Equity (0.47) |
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Altimmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.